Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
We are delighted to announce the 2020 Digital Scrip Awards winners!
Sponsors
We are delighted to announce the 2020 Digital Scrip Award Winners!. Click here to view the full winners list.
The Digital Scrip Awards took place on 2 December 2020 and acknowledged the outstanding achievements taking place across the industry. We’d like to thank everyone who entered, sponsored and attended the digital Scrip Awards, and congratulations to all our winners. We hope to be able to see you all in person in 2021!
If you would like to be kept up to date with Scrip Awards 2021 launch dates - please contact Jo Kirkpatrick on jo.kirkpatrick@informa.com
Since they began, the Scrip Awards has sought to applaud the essential role that the pharmaceutical, biotech and other allied industries play in improving healthcare. Its trophies span the entire range of industry activities, from new drug launches and clinical trials, to innovative deals, outsourcing and fundraising. In the current climate it’s more important than ever to recognize what has been achieved.
This year, we have introduced a new category – China Biopharma Leadership Award – to reflect the rapid maturing of China’s biopharma sector, thanks to the development of homegrown biopharma companies, CDMOs and increasing investment in the market from global multinational biopharma companies.
Over the past 16 years, the Scrip Awards has carved out a unique place in the industry calendar, with attendees coming from around the world to the prestigious ceremony.
Headline Sponsor
ICON plc is a world-leading healthcare intelligence and clinical research organisation, with over 38,000 employees in 93 locations in 46 countries around the world, headquartered in Dublin. We advance clinical research by providing outsourced development and commercialisation services to pharmaceutical, biotechnology, medical device, and government and public health organisations. Our services span the entire lifecycle of product development, from molecule to medicine, across a broad range of therapeutic areas. We develop new innovations, drive emerging therapies forward, and improve patient lives.
2021 sponsors include:
Bioclinica, an ERT company, is an integrated clinical life science solutions provider, leveraging knowledge and insight to minimize risk and accelerate development in clinical trials. Through deep medical, scientific, and technology expertise, the company provides medical imaging and cardiac safety services, clinical endpoint adjudication, clinical trial software, and drug safety solutions. For more information, visit www.bioclinica.com.
IQVIA™ is a leading global provider of information, innovative technology solutions and contract research services focused on using data and science to help healthcare clients find better solutions for their patients. Formed through the merger of IMS Health and Quintiles, IQVIA offers a broad range of solutions that harness advances in healthcare information, technology, analytics and human ingenuity to drive healthcare forward.
IQVIA enables companies to rethink approaches to clinical development and commercialization, innovate with confidence as well as accelerate meaningful healthcare outcomes. IQVIA has approximately 55,000 employees in more than 100 countries, all committed to making the potential of Human Data Science a reality. IQVIA’s approach to Human Data Science is powered by the IQVIA CORE™, driving unique actionable insights at the intersection of big data, advanced technology and analytics with extensive industry knowledge. To learn more, visit www.iqvia.com.
MSD has a strong history of success in translating cutting-edge research into life-saving medical breakthroughs. Our scientific advances have made a difference in the lives of millions of patients worldwide. From MSD’s development of the first measles and mumps vaccines to treatments for cancer and diabetes, we are an industry leader in bringing forth innovative new medicines. In 2019 MSD had sales of more than $46 billion and we operate in more than 140 countries.
Parexel partners with life science and biopharmaceutical customers across the globe to help transform scientific discoveries into innovative new therapies that improve patient health. Our full-service offerings span early phase to post-marketing approval and include expert consultation across regulatory and consulting, laboratory services, real-world evidence, market access and more. With more than 35 years of experience, our therapeutic, technical and functional abilities are underpinned by a deep conviction In what we do best: supporting our customers in fulfilling the unmet medical needs of patients worldwide.
WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve the productivity of advancing healthcare products through cost-effective and efficient, socially responsible and sustainable solutions. With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec's open-access platform is enabling more than 5,200 collaborators from over 30 countries to improve the health of those in need – and to realize our vision that "every drug can be made and every disease can be treated."
Associate Sponsor:
Takeda is a patient-focused, values-based, R&D-driven global biopharmaceutical company committed to bringing Better Health and a Brighter Future to people worldwide. Our passion and pursuit of potentially life-changing treatments for patients are deeply rooted in over 230 years of distinguished history in Japan.
Our global team of researchers and scientists, together with our partners, harness cutting-edge science to push the boundaries of what is possible in order to bring transformative, life-changing therapies to patients worldwide.
Takeda seeks to improve people's lives by researching, developing and bringing to market new and better medicines that help to address the nation's most pressing healthcare needs. We focus on the areas of oncology, gastroenterology and diabetes.
